Archivel Farma

Executive Summary

Archivel Farma is a privately held Spanish biotech founded in 2004, specializing in immunotherapeutic products and freeze-dried biologicals. The company is advancing its proprietary vaccine candidate RUTI® for immunotherapy applications, while also operating as a contract development and manufacturing organization (CDMO) for early-phase clinical batches. With its dual focus, Archivel leverages established expertise in injectable biologics to support both internal pipeline development and external partnerships. While financial details and clinical stage remain undisclosed, the company's long-standing presence in Barcelona suggests resilience and a steady operational track record. The convergence of vaccine innovation and CDMO services positions Archivel to capture value from growing demand for biologics manufacturing, though near-term value inflection hinges on RUTI® program progress.

Upcoming Catalysts (preview)

• Q2 2026RUTI® Phase 2 clinical data readout55% success
• Q3 2026New CDMO partnership for early-phase biologics70% success
• TBDRegulatory milestone for RUTI® (e.g., orphan drug designation in TB)40% success